HAEP (Health Axis Europe Partnering): Tailored matching between global pharmaceutical companies and innovators (academia, SMEs, startups)

​

• Custom fit connection: HAEP provides tailored project and technology scouting

• Critical mass: HAEP sources technologies from a large international network of innovators

• Reach: HAEP enables innovation pitches in front of high-level decision makers of global players Critical mass through HAE

HeiDelberg Discovery: Looking for new ways to finance and drive early stage life science projects in the region

​

• Committed translational funding and drug discovery expertise for novel life science technologies

• Joint investment industry and academia supported by public funding

Learning from international models                         -Conception phase ongoing-

HeiDelberg Incubator: working towards the establishment of a life science incubator in the region

​

• Space and resources to nurture early stage projects

• Cross fertilization among young entrepreneurs

• Mentoring from experienced entrepreneurs

• Investor ecosystem accompanying startups early on

• Joint commitment of all stakeholders (industry, academia, public)

​

Learning from internationally successful incubator models       ​-Conception phase ongoing-

"Biolabs-Heidelberg-Projekt" - EY Deutscher Biotechnologie-Report 2020 >>